Opaleye Management’s Indaptus Therapeutics INDP Stock Holding History

Opaleye Management’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-78	Closed	-$1.03M	–	44
2016 Q3	$1.03M	Sell	78 -212	-73%	-$2.64M	0.54%	38
2016 Q2	$2.99M	Buy	290 +5	+2%	+$44.9K	2%	19
2016 Q1	$2.63M	Buy	285 +4	+1%	+$37.2K	1.64%	26
2015 Q4	$3.38M	Hold	281	–	–	1.41%	30
2015 Q3	$3.53M	Buy	+281	New	+$3.69M	1.74%	24

Other funds holding INDP

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Opaleye Management's INDP Position: Q4 2016 in Review

Opaleye Management sold out of Indaptus Therapeutics (INDP) in Q4 2016, closing a stake of 78 shares — an estimated $1.03M sold.

Opaleye Management first reported a position in INDP in Q3 2015 and held it in 5 quarters. The position peaked at $3.53M in Q3 2015. 5 funds tracked by Wall St. Rank hold INDP as of Q4 2016.

Opaleye Management reported no remaining Indaptus Therapeutics position as of Q4 2016 after selling out during the quarter.
Opaleye Management sold 78 Indaptus Therapeutics shares in Q4 2016, an estimated $1.03M.
Opaleye Management first reported a position in Indaptus Therapeutics in Q3 2015 and held it in 5 quarters.
Opaleye Management's Indaptus Therapeutics position peaked at $3.53M in Q3 2015.
5 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2016.

Based on Opaleye Management's 13F filing for Q4 2016, filed 21 Feb 2017.